Recently, Kam et al. [36] reported an inhibition of HMGB1 with sivelestat to be able to promote myelodysplastic syndrome cell death and alter innate immune responses via suppression of NFkB pathways. This evidence concerns the gene HMGB1 and myelodysplastic syndrome.